Inhibrx
La Jolla
About Inhibrx
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases, and infectious diseases. Inhibrx has collaborations with Celgene and Bluebird Bio and has received awards from several granting agencies, including NIH, NIAID, and CARB-X.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $494.6M
- Funding stage: M&A
- Last round: Post-IPO Debt (Mar 2026)
- Ticker: nasdaq:INBX
- Website: inhibrx.com
- Phone: (858) 795-4220
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/inhibrx-146627 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.